Rosetta Genomics Company Profile (NASDAQ:ROSG)

About Rosetta Genomics (NASDAQ:ROSG)

Rosetta Genomics logoRosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ROSG
  • CUSIP: N/A
  • Web:
  • Market Cap: $3.21 million
  • Outstanding Shares: 1,868,000
Average Prices:
  • 50 Day Moving Avg: $2.36
  • 200 Day Moving Avg: $5.13
  • 52 Week Range: $1.40 - $18.60
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.43
  • P/E Growth: -0.02
Sales & Book Value:
  • Annual Revenue: $9.23 million
  • Price / Sales: 0.35
  • Book Value: $2.40 per share
  • Price / Book: 0.72
  • EBIDTA: ($14,760,000.00)
  • Net Margins: -167.32%
  • Return on Equity: -127.01%
  • Return on Assets: -103.27%
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 2.70%
  • Quick Ratio: 2.70%
  • Average Volume: 131,461 shs.
  • Beta: -5.34
  • Short Ratio: 0.55

Frequently Asked Questions for Rosetta Genomics (NASDAQ:ROSG)

What is Rosetta Genomics' stock symbol?

Rosetta Genomics trades on the NASDAQ under the ticker symbol "ROSG."

How were Rosetta Genomics' earnings last quarter?

Rosetta Genomics Ltd. (NASDAQ:ROSG) released its quarterly earnings data on Thursday, May, 19th. The company reported ($0.18) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.02. The firm had revenue of $2.60 million for the quarter, compared to the consensus estimate of $3.36 million. Rosetta Genomics had a negative net margin of 167.32% and a negative return on equity of 127.01%. View Rosetta Genomics' Earnings History.

Where is Rosetta Genomics' stock going? Where will Rosetta Genomics' stock price be in 2017?

2 analysts have issued 1-year price objectives for Rosetta Genomics' shares. Their forecasts range from $0.82 to $3.50. On average, they expect Rosetta Genomics' share price to reach $2.16 in the next year. View Analyst Ratings for Rosetta Genomics.

Who are some of Rosetta Genomics' key competitors?

Who owns Rosetta Genomics stock?

Rosetta Genomics' stock is owned by many different of institutional and retail investors. Top institutional investors include Morgan Stanley (3.34%). View Institutional Ownership Trends for Rosetta Genomics.

Who sold Rosetta Genomics stock? Who is selling Rosetta Genomics stock?

Rosetta Genomics' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. View Insider Buying and Selling for Rosetta Genomics.

How do I buy Rosetta Genomics stock?

Shares of Rosetta Genomics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Rosetta Genomics stock cost?

One share of Rosetta Genomics stock can currently be purchased for approximately $1.72.

Analyst Ratings

Consensus Ratings for Rosetta Genomics (NASDAQ:ROSG) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.16 (25.58% upside)

Analysts' Ratings History for Rosetta Genomics (NASDAQ:ROSG)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/6/2017AegisReiterated RatingBuy$3.50N/AView Rating Details
9/7/2016S&P Equity ResearchLower Price Target$0.94 -> $0.82N/AView Rating Details
6/13/2016Cantor FitzgeraldReiterated RatingBuyN/AView Rating Details
3/28/2016Barrington ResearchLower Price TargetOutperform$5.00 -> $3.50N/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Rosetta Genomics (NASDAQ:ROSG)
Earnings by Quarter for Rosetta Genomics (NASDAQ:ROSG)
Earnings History by Quarter for Rosetta Genomics (NASDAQ:ROSG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/26/2016Q216($0.17)($0.16)$2.89 million$2.41 millionViewListenView Earnings Details
5/19/2016Q116($0.16)($0.18)$3.36 million$2.60 millionViewListenView Earnings Details
3/23/2016Q415($0.33)($0.14)$3.50 million$3.60 millionViewListenView Earnings Details
12/1/2015Q315$0.27$2.43 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Rosetta Genomics (NASDAQ:ROSG)
Current Year EPS Consensus Estimate: $-5.64 EPS
Next Year EPS Consensus Estimate: $-3.96 EPS


Dividend History for Rosetta Genomics (NASDAQ:ROSG)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Rosetta Genomics (NASDAQ:ROSG)
No insider trades for this company have been tracked by


Headline Trends for Rosetta Genomics (NASDAQ:ROSG)
Latest Headlines for Rosetta Genomics (NASDAQ:ROSG)
DateHeadline logoRosetta Genomics Enters Collaboration to Develop a microRNA Classifier Relating to Patients with Non-Small Cell Lung Cancer Considered for Treatment with Immuno-oncology Drugs - May 23 at 9:34 AM logoRosetta Genomics Focusing Efforts on Improving Cash Position through Sale of the PersonalizeDx Business and Monetizing IP - May 22 at 9:19 AM logoRosetta Genomics Announces Favorable Results from Two Pilot Studies Comparing RosettaGX Reveal(TM) and the Afirma GEC Assay for the Classification of Indeterminate Thyroid Nodules - May 12 at 10:52 PM logoZacks: Brokerages Set $34.01 Price Target for Rosetta Genomics Ltd. (ROSG) - May 8 at 11:28 AM logoRosetta Genomics Expands International Access for RosettaGX Reveal(TM) through Agreement with Cytolog Laboratories in Brazil - May 5 at 8:09 AM logoRosetta Genomics Receives Final Approval from New York State for First-of-its-kind Thyroid Cancer Diagnostic Assay - May 4 at 7:49 PM logoFavorable News Coverage Extremely Likely to Impact Rosetta Genomics (ROSG) Share Price - May 2 at 9:46 AM logoRosetta Genomics to Increase Investment in RosettaGX Reveal(TM) and Explore Strategic Alternatives for the PersonalizeDx Business - May 2 at 9:45 AM logoRosetta Genomics Expands Patent Portfolio in Europe and Japan - May 1 at 10:09 AM logoNew Data Highlighting the Powerful Performance of RosettaGX Reveal(TM) in Identifying Medullary Thyroid Cancer to be Presented at the AACE 2017 Annual Meeting - April 27 at 10:59 AM logoRosetta Genomics (ROSG) Earning Very Favorable Media Coverage, Analysis Shows - April 22 at 7:47 AM logo Rosetta Genomics Ltd. (ROSG) Receives Consensus Recommendation of "Strong Buy" from Brokerages - April 21 at 7:31 AM logoVery Favorable Press Coverage Extremely Likely to Affect Rosetta Genomics (ROSG) Stock Price - April 18 at 10:23 AM logoZacks: Analysts Set $34.01 Target Price for Rosetta Genomics Ltd. (ROSG) - April 6 at 5:18 PM logoEdited Transcript of ROSG earnings conference call or presentation 30-Mar-17 2:00pm GMT - March 31 at 12:52 AM logoRosetta Genomics Reports 2016 Fourth Quarter and Full Year Financial Results - March 30 at 7:51 PM logoFull Year 2016 Rosetta Genomics Ltd Earnings Release - Before Market Open - March 30 at 7:51 PM logoRosetta Genomics Ltd. (ROSG) Set to Announce Quarterly Earnings on Thursday - March 29 at 9:05 AM logoRosetta Genomics to Host 2016 Fourth Quarter and Year End Financial Results and Business Update Conference Call on March 30, 2017 - March 23 at 8:20 AM logoRosetta Genomics Fortifies Patent Protection for its Unique RosettaGX RevealTM Assay - March 20 at 5:40 PM logoRosetta Genomics (ROSG) Reports Patent for its Unique RosettaGX Reveal Assay - - March 20 at 9:14 AM logoSplits Calendar: Rosetta Genomics splits before market open today (1:12 ratio) - March 17 at 7:40 PM logoRosetta Genomics (ROSG) 1-for-12 Reverse Stock Split Effective Tomorrow - - March 17 at 1:29 AM logo12:02 pm Rosetta Genomics announces 1:12 reverse stock split; will begin trading on a split-adjusted basis tomorrow at the open - March 16 at 8:27 PM logoRosetta Genomics Announces 1-for-12 Reverse Stock Split - March 16 at 8:27 PM logoRosetta Genomics Closes Second Tranche of Previously Announced Private Placement of Convertible Debentures - Business Wire (press release) - February 24 at 8:00 AM logoRosetta Genomics Closes Second Tranche of Previously Announced Private Placement of Convertible Debentures - February 23 at 7:46 PM logoRosetta Genomics Reports Preliminary RosettaGX Reveal™ Financial Results for the 2016 Fourth Quarter and Year - February 8 at 11:30 PM logo8:03 am Rosetta Genomics: USPTO has granted two patents, both divisional patents of the parent application titled 'microRNAs and uses thereof' - February 6 at 7:41 PM logoRosetta Genomics Announces Key U.S. Patent Allowances for Two RosettaGx Reveal TM microRNAs - February 6 at 8:43 AM logoRosetta Genomics Announces Key U.S. Patent Allowances for Two RosettaGx RevealTM microRNAs - February 6 at 8:43 AM logoAegis Restates 'Buy' Rating on Shares of Rosetta Genomics Ltd. (NAS:ROSG) - January 11 at 9:49 PM logoRosetta Genomics Reports Third Quarter 2016 Financial Results - December 20 at 2:19 PM logoBRIEF-Rosetta Genomics files for resale of up to 15.5 mln of co's ordinary shares by selling stockholders - December 8 at 8:01 PM logoRosetta Genomics to Present at the 9th Annual LD Micro Main Event - December 1 at 8:15 AM logoQ3 2016 Rosetta Genomics Ltd Earnings Release - After Market Close - November 30 at 12:42 PM logoRosetta Genomics (ROSG) Prices of $5M Concurrent Registered Direct and Private Placement - November 24 at 10:34 AM logoRosetta Genomics (ROSG) Prices of $5M Concurrent Registered Direct and Private Placement - - November 23 at 7:29 PM logoRosetta Genomics (ROSG), Sheba Medical Center Enter MicroRNA-Based BiomarkerResearch Collaboration - - November 22 at 7:25 PM logoRosetta Genomics Enters Research Collaboration using microRNA Biomarkers to Predict Response to Leading Immuno-Oncology Drug Nivolumab in Lung Cancer Patients - November 21 at 12:37 PM



Rosetta Genomics (ROSG) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff